Bristol-Myers to buy Amylin for about $5.3 billion






Bristol-Myers to buy Amylin for about $5.3 billion



(Reuters) - Bristol-Myers Squibb Co has agreed to buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion, or $31 per share, in cash, giving Bristol-Myers a stake in the future of diabetes drugs Byetta and Bydureon. Bristol-Myers said late on Friday it had also reached a follow-on deal with UK-based AstraZeneca Plc to collaborate on the development of Amylin's products once the buyout is completed. AstraZeneca will pay $3.4 billion in cash for these rights. The boards of directors at Amylin, Bristol and AstraZeneca have approved the two transactions, the companies said. ...






Popular posts from this blog

Which Wedding Style Is The Best Fit For A Couple?

Saudi Arabia adopts measures to limit virus infection during Haj

Fake ADHD drug Adderall sold online, U.S. FDA warns